{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:40:59Z","timestamp":1789908059123,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T00:00:00Z","timestamp":1418947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s11060-014-1691-z","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T08:07:31Z","timestamp":1418976451000},"page":"135-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma"],"prefix":"10.1007","volume":"122","author":[{"given":"Douglas E.","family":"Ney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Damek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie E.","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. K.","family":"Kleinschmidt-DeMasters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen E.","family":"Waziri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin O.","family":"Lillehei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,19]]},"reference":[{"key":"1691_CR1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466","journal-title":"Lancet Oncol"},{"key":"1691_CR2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"1691_CR3","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","volume":"310","author":"A Omuro","year":"2013","unstructured":"Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842\u20131850","journal-title":"JAMA"},{"key":"1691_CR4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrn2175","volume":"8","author":"RK Jain","year":"2007","unstructured":"Jain RK, di Tomaso E, Duda DG et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610\u2013622","journal-title":"Nat Rev Neurosci"},{"key":"1691_CR5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccr.2005.07.014","volume":"8","author":"Z Fuks","year":"2005","unstructured":"Fuks Z, Kolesnick R (2005) Engaging the vascular component of the tumor response. Cancer Cell 8:89\u201391","journal-title":"Cancer Cell"},{"key":"1691_CR6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1535-6108(04)00118-7","volume":"5","author":"GL Semenza","year":"2004","unstructured":"Semenza GL (2004) Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 5:405\u2013406","journal-title":"Cancer Cell"},{"key":"1691_CR7","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.ijrobp.2006.11.011","volume":"67","author":"PR Wachsberger","year":"2007","unstructured":"Wachsberger PR, Burd R, Cardi C et al (2007) VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 67:1526\u20131537","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"307","key":"1691_CR8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","volume":"2005","author":"RK Jain","year":"2005","unstructured":"Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005(307):58\u201362","journal-title":"Science"},{"key":"1691_CR9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ccr.2005.06.016","volume":"8","author":"BJ Moeller","year":"2005","unstructured":"Moeller BJ, Dreher MR, Rabbani ZN et al (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8:99\u2013110","journal-title":"Cancer Cell"},{"issue":"3","key":"1691_CR10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","volume":"2003","author":"GL Semenza","year":"2003","unstructured":"Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003(3):721\u2013732","journal-title":"Nat Rev Cancer"},{"key":"1691_CR11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2009.02.037","volume":"76","author":"CH Crane","year":"2010","unstructured":"Crane CH, Eng C, Feig BW et al (2010) Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 76:824\u2013830","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1691_CR12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijrobp.2013.10.034","volume":"88","author":"P Das","year":"2014","unstructured":"Das P, Eng C, Rodriguez-Bigas MA et al (2014) Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys 88:301\u2013305","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1691_CR13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1179\/1973947813Y.0000000163","volume":"26","author":"AG Morganti","year":"2014","unstructured":"Morganti AG, Mignogna S, Caravatta L et al (2014) FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I\u2013II study. J Chemother 26:353\u2013358","journal-title":"J Chemother"},{"key":"1691_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2013.10.022","volume":"88","author":"T Schefter","year":"2014","unstructured":"Schefter T, Winter K, Kwon JS et al (2014) RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys 88:101\u2013105","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1691_CR15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2012.01.035","volume":"84","author":"K Reddy","year":"2012","unstructured":"Reddy K, Damek D, Gaspar LE et al (2012) Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 84:655\u2013660","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1691_CR16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280","journal-title":"J Clin Oncol"},{"key":"1691_CR17","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","volume":"22","author":"W Roa","year":"2004","unstructured":"Roa W, Brasher PM, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583\u20131588","journal-title":"J Clin Oncol"},{"key":"1691_CR18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11060-008-9689-z","volume":"91","author":"G Minniti","year":"2009","unstructured":"Minniti G, De Sanctis V, Muni R et al (2009) Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 91:95\u2013100","journal-title":"J Neurooncol"},{"key":"1691_CR19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0360-3016(03)01623-7","volume":"58","author":"NS Floyd","year":"2004","unstructured":"Floyd NS, Woo SY, Teh BS et al (2004) Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 58:721\u2013726","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1691_CR20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0360-3016(03)00819-8","volume":"58","author":"K Sultanem","year":"2004","unstructured":"Sultanem K, Patrocinio H, Lambert C et al (2004) The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys 58:247\u2013252","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1691_CR21","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2010.07.021","volume":"81","author":"C Chen","year":"2011","unstructured":"Chen C, Damek D, Gaspar LE et al (2011) Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 81:1066\u20131074","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1691_CR22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijrobp.2010.04.069","volume":"81","author":"KE Rusthoven","year":"2011","unstructured":"Rusthoven KE, Olsen C, Franklin W, Kleinschmidt-DeMasters BK, Kavanagh BD, Gaspar LE, Lillehei K, Waziri A, Damek DM, Chen C (2011) Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. Int J Radiat Oncol Biol Phys 81:211\u2013217","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1691_CR23","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1158\/1078-0432.CCR-14-0822","volume":"20","author":"A Omuro","year":"2014","unstructured":"Omuro A, Beal K, Gutin P, Karimi S et al (2014) Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res 20:5023\u20135031","journal-title":"Clin Cancer Res"},{"key":"1691_CR24","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","volume":"79","author":"VA Levin","year":"2011","unstructured":"Levin VA, Bidaut L, Hou P et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79:1487\u20131495","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1691_CR25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.ijrobp.2005.12.005","volume":"64","author":"T Iuchi","year":"2006","unstructured":"Iuchi T, Hatano K, Narita Y et al (2006) Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64:1317\u20131324","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1691_CR26","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1200\/JCO.2010.31.4815","volume":"29","author":"DS Jeyaretna","year":"2011","unstructured":"Jeyaretna DS, Curry WT Jr, Batchelor TT et al (2011) Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol 29:e159\u2013e162","journal-title":"J Clin Oncol"},{"key":"1691_CR27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722","journal-title":"N Engl J Med"},{"key":"1691_CR28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS et al (2014) Randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708","journal-title":"N Engl J Med"},{"key":"1691_CR29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clineuro.2008.11.003","volume":"111","author":"C Peca","year":"2009","unstructured":"Peca C, Pacelli R, Elefante A et al (2009) Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin Neurol Neurosurg 111:331\u2013334","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1691-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-014-1691-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1691-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T15:47:06Z","timestamp":1566143226000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-014-1691-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["1691"],"URL":"https:\/\/doi.org\/10.1007\/s11060-014-1691-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,19]]}}}